Overview
Clinically curated DNA+RNA panel covering 52 actionable genes for rapid routine oncology diagnostics.
Why this Test Matters
Precision oncology depends on identifying clinically actionable genomic alterations. This assay helps clinicians select targeted therapies, evaluate immunotherapy eligibility, identify prognostic biomarkers, detect resistance mechanisms, and match patients to suitable clinical trials while minimizing sequential testing.
Who Should Consider this Test?
● Newly diagnosed solid tumors ● Lung, colorectal, breast and thyroid cancers ● Patients requiring rapid actionable biomarkers
Applicable Cancer Types
Most solid tumors
What is Covered?
- 52 genes
- SNVs
- InDels
- CNVs
- RNA fusions
Clinical Utility
- Treatment selection
- Prognostic and predictive biomarkers
- Clinical trial matching
- Identification of actionable alterations
- Comprehensive clinical interpretation
Technology
Integrated DNA+RNA workflowkey Features
| Parameter | Details |
|---|---|
|
Sample Type |
FFPE tissue |
|
Samples |
1 sample |
|
Turnaround Time |
10–14 working days |
|
Report Includes |
Variant interpretation, therapy associations, clinically actionable biomarkers |
|
Quality |
High-depth NGS with rigorous QC |